Dasatinib may be effective against several cancers
the ONA take:
According to a new study published in the journal Molecular Carcinogenesis, dasatinib (Sprycel) may be effective for the treatment of breast, skin, and various other cancers. Researchers found that dasatinib, a tyrosine kinase inhibitor that targets the Bcr-Abl oncogene, was effective in vitro at inhibiting Fyn, a protein similar to Bcr-Abl.
Fyn is known for being involved cell-cell adhesion and cell migration and is found in brain, breast, head-and-neck, pancreatic, and skin cancers.
Mitchell Dennings, PhD, and his colleagues applied dasatinib to cancer cells in vitro and observed the cells clumping together as well a halt in cell migration. The team found similar results when using breast cancer cells. When administered to mice with skin cancer, dasatinib decreased the quantity and size of their tumors.
Clinical trials are currently underway to study dasatinib's effects in patients with acute lymphoblastic lymphoma, endometrial cancer, gastrointestinal stromal cancer, Hodgkin's lymphoma, melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, and prostate cancer.
Dasatinib was initially approved by the U.S. Food and Drug Administration in 2006 and is indicated for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. It is administered orally once daily.
Dasatinib shows promise for treating skin, breast and several other cancers.
Dasatinib fights leukemia by checking the uncontrolled growth of cancer cells. But when used against other cancer cells, researchers found, the drug employs a different strategy: It causes the cells to clump together, thus preventing them from migrating. Without the ability to migrate, cancer cells cannot metastasize (spread to other parts of the body).
Mitchell Denning, PhD, and colleagues discovered the molecular mechanism behind this cell-cell adhesion. The researchers reported their findings in a study published online ahead of print in the journal Molecular Carcinogenesis.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|